On Friday 03/17/2023 the closing price of the Coronado Biosciences Inc share was $0.70 on NAS.
Compared to the opening price on Friday 03/17/2023 on NAS of $0.73, this is a drop of 4.30%.
Coronado Biosciences Inc's market capitalization is $79.78 M by 110.49 M shares outstanding.
Is Coronado Biosciences stock a Buy, Sell or Hold?
Coronado Biosciences stock hasn't recieved a clear consensus rating. The average rating score is and is based on 1 buy ratings, 1 hold ratings, and 0 sell ratings.What was the 52-week low for Coronado Biosciences stock?
The low in the last 52 weeks of Coronado Biosciences stock was 0.48. According to the current price, Coronado Biosciences is 145.74% away from the 52-week low.What was the 52-week high for Coronado Biosciences stock?
The high in the last 52 weeks of Coronado Biosciences stock was 1.53. According to the current price, Coronado Biosciences is 45.90% away from the 52-week high.What are analysts forecasts for Coronado Biosciences stock?
The 2 analysts offering price forecasts for Coronado Biosciences have a median target of 5.50, with a high estimate of 6.00 and a low estimate of 5.00. The median estimate represents a 12.73 difference from the last price of 0.70.Coronado Biosciences Stock Snapshot
0.73
Bid
800.00
Bid Size
0.74
Ask
2,800.00
Ask Size
3/17/2023
Date
8:00 PM
Time
284,728.00
Volume
0.74
Prev. Close
0.73
Open
79.78 M
Market Cap
110.49 M
Number of Shares
0.70
Day Low
0.74
Day High
0.70
0.48
52 Week Low
1.53
52 Week High
0.70
-3.05
P/E Ratio
58.26
Free Float in %
-0.84
EPS 2023
Coronado Biosciences News More News
Coronado Biosciences Historical Prices
Date | Open | Close | Daily High | Daily Low |
---|
Price change over selected period:
0%
0
Coronado Biosciences Analyst Data
Total Analysts: 2
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 5.00
Median: 5.50
Highest: 6.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Coronado Biosciences Analyst Opinions
- All
- Buy
- Hold
- Sell
08/04/22 | Ladenburg Thalmann & Co. Inc. | Maintained Buy | $6 | ||
04/20/21 | ROTH Capital Partners, LLC | Maintained Buy | $5 |
Coronado Biosciences Estimates* in USD
2023 | 2024 | 2025 | 2026 | |
---|---|---|---|---|
Revenue | 86 | 163 | 254 | 380 |
Dividend | - | - | - | - |
Dividend Yield (in %) | - | - | - | - |
EPS | -0.84 | 0.24 | 0.49 | 1.69 |
P/E Ratio | -0.87 | 2.98 | 1.47 | 0.43 |
EBIT | -190 | -138 | -63 | 33 |
EBITDA | -252 | - | - | - |
Net Profit | -96 | 8 | 25 | 136 |
Net Profit Adjusted | -145 | -65 | -54 | 33 |
Pre-Tax Profit | -204 | -152 | -73 | 23 |
Net Profit (Adjusted) | -128 | -95 | 2 | - |
EPS (Non-GAAP) ex. SOE | -0.58 | 1.59 | - | - |
EPS (GAAP) | -0.84 | 0.24 | 0.49 | 1.69 |
Gross Income | 76 | 172 | 210 | 266 |
Cash Flow from Investing | -4 | -4 | -4 | -5 |
Cash Flow from Operations | -203 | -152 | -76 | -37 |
Cash Flow from Financing | 118 | 135 | 140 | 88 |
Cash Flow per Share | - | - | - | - |
Free Cash Flow | - | - | - | - |
Free Cash Flow per Share | - | - | - | - |
Book Value per Share | - | - | - | - |
Net Debt | - | - | - | - |
Research & Development Exp. | 143 | 153 | 151 | 171 |
Capital Expenditure | 4 | 4 | 4 | 5 |
Selling, General & Admin. Exp. | 127 | 142 | 151 | 163 |
Shareholder’s Equity | 74 | 87 | 113 | 154 |
Total Assets | 285 | 312 | 361 | 409 |
Previous Quarter ending 12/31/22 |
Current Quarter ending 03/31/23 |
Next Quarter ending 06/30/23 |
Current Year ending 12/31/23 |
Next Year ending 12/31/24 |
|
---|---|---|---|---|---|
Earnings Estimates | |||||
No. of Analysts | - | 3 | 3 | 5 | 5 |
Average Estimate | - | -0.207 USD | -0.210 USD | -0.836 USD | 0.244 USD |
Year Ago | - | -0.180 USD | -0.240 USD | - | -0.836 USD |
Publish Date | - | 5/11/2023 | 8/10/2023 | - | - |
Revenue Estimates | |||||
No. of Analysts | 5 | 3 | 3 | 5 | 5 |
Average Estimate | 22 USD | 18 USD | 18 USD | 86 USD | 163 USD |
Year Ago | 18 USD | 24 USD | 19 USD | - | 86 USD |
Publish Date | 3/20/2023 | 5/11/2023 | 8/10/2023 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Coronado Biosciences Insider Activity
Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
---|---|---|---|---|---|---|
Lu Lucy | 02/09/2023 | 11,976.00 | 133,379.00 | 0.84 | Buy | No |
Jin David | 02/09/2023 | 35,928.00 | 1,438,757.00 | 0.84 | Buy | No |
ROSENWALD LINDSAY A MD | 02/09/2023 | 2,395,209.00 | 15,349,091.00 | 0.84 | Buy | No |
Rowinsky Eric K | 02/09/2023 | 11,976.00 | 931,976.00 | 0.84 | Buy | No |
WEISS MICHAEL S | 02/09/2023 | 1,197,604.00 | 14,752,034.00 | 0.84 | Buy | No |
LOBELL J JAY | 02/09/2023 | 299,401.00 | 1,635,401.00 | 0.84 | Buy | No |
LOBELL J JAY | 12/31/2022 | 100,000.00 | 1,336,000.00 | n/a | Buy | No |
Harvey Jimmie | 12/31/2022 | 100,000.00 | 950,000.00 | n/a | Buy | No |
ROSENWALD LINDSAY A MD | 12/31/2022 | 1,219,294.00 | 12,953,882.00 | n/a | Buy | No |
WEISS MICHAEL S | 12/31/2022 | 1,219,294.00 | 13,554,430.00 | n/a | Buy | No |
Hoenlein Malcolm | 12/31/2022 | 50,000.00 | 535,636.00 | n/a | Buy | No |
Lu Lucy | 12/31/2022 | 50,000.00 | 121,403.00 | n/a | Buy | No |
Rowinsky Eric K | 12/31/2022 | 100,000.00 | 920,000.00 | n/a | Buy | No |
Lorenz Kevin | 12/31/2022 | 50,000.00 | 314,572.00 | n/a | Buy | No |
Klein Dov | 12/31/2022 | 100,000.00 | 851,015.00 | n/a | Buy | No |
Lu Lucy | 12/15/2022 | 30,000.00 | 71,403.00 | n/a | Buy | No |
ROSENWALD LINDSAY A MD | 11/30/2022 | 100,000.00 | 11,730,324.00 | 0.68 | Buy | No |
ROSENWALD LINDSAY A MD | 11/29/2022 | 5,000.00 | 11,630,324.00 | 0.56 | Buy | No |
Jin David | 11/29/2022 | 5,000.00 | 1,402,829.00 | 0.56 | Buy | No |
Jin David | 10/25/2022 | 1,350,000.00 | 1,397,829.00 | n/a | Buy | No |
ROSENWALD LINDSAY A MD | 10/20/2022 | 100,000.00 | 11,625,324.00 | 0.70 | Buy | No |
ROSENWALD LINDSAY A MD | 05/31/2022 | 4,264.00 | 11,734,588.00 | 0.73 | Buy | No |
LOBELL J JAY | 12/31/2021 | 100,000.00 | 1,236,000.00 | n/a | Buy | No |
Rowinsky Eric K | 12/31/2021 | 100,000.00 | 820,000.00 | n/a | Buy | No |
Klein Dov | 12/31/2021 | 100,000.00 | 751,015.00 | n/a | Buy | No |
Coronado Biosciences Dividend Calendar
Date | Name | Dividend | *yield | Currency |
---|---|---|---|---|
2021 | Coronado Biosciences Inc | - | - | USD |
2020 | Coronado Biosciences Inc | - | - | USD |
2019 | Coronado Biosciences Inc | - | - | USD |
2018 | Coronado Biosciences Inc | - | - | USD |
2017 | Coronado Biosciences Inc | - | - | USD |
2016 | Coronado Biosciences Inc | - | - | USD |
2015 | Coronado Biosciences Inc | - | - | USD |
2014 | Coronado Biosciences Inc | - | - | USD |
2013 | Coronado Biosciences Inc | - | - | USD |
2012 | Coronado Biosciences Inc | - | - | USD |
2011 | Coronado Biosciences Inc | - | - | USD |
2010 | Coronado Biosciences Inc | - | - | USD |
2009 | Coronado Biosciences Inc | - | - | USD |
*Yield of the Respective Date
Coronado Biosciences Inc Calendar
Event | Estimate | Info | Date |
---|---|---|---|
Earnings Report | - | Q4 2022 Earnings Release | 03/20/2023 |
Earnings Report | -0.207 USD | Q1 2023 Earnings Release | 05/11/2023 |
Earnings Report | -0.210 USD | Q2 2023 Earnings Release | 08/10/2023 |
Earnings Report | - | Q3 2023 Earnings Release | 11/13/2023 |
Coronado Biosciences Profile
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
Moody’s Daily Credit Risk Score
Coronado Biosciences Shareholder
Owner | in % |
---|---|
Freefloat | 62.15 |
Lindsay Allan Rosenwald, MD | 13.89 |
Michael Sean Weiss | 13.35 |
Nantahala Capital Management LLC | 7.21 |
DAK Capital, Inc. | 5.48 |
Vanguard Group, Inc. (Subfiler) | 4.59 |
Jefferies Financial Services, Inc. | 3.89 |
Tang Capital Management LLC | 3.80 |
Vanguard Total Stock Market Index Fund | 1.94 |
Opaleye Management, Inc. | 1.86 |
Vanguard Explorer Fund | 1.57 |
J. Jay Lobell | 1.48 |
iShares Russell 2000 ETF | 1.44 |
David Jin | 1.30 |
FCP Medical - BioHealth | 1.19 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.